ABOUT DR. BRITT CRAIGLOW, MD

Dr. Craiglow is double board-certified in both dermatology and pediatric dermatology, has authored over sixty publications and is regularly invited to speak at national and international conferences. While she treats the full range of dermatologic diseases, her particular areas of interest include hair loss (alopecia), atopic dermatitis (eczema), psoriasis, vitiligo, acne and rare and inherited skin diseases.

After completing her medical training, Dr. Craiglow spent several years on the full-time faculty at Yale before transitioning to private practice in order to be able to focus more of her energy on patient care, which is her true passion. She continues to maintain an active academic presence, publishing regularly in major medical journals and supervising and teaching dermatology residents and medical students. She also volunteers on a variety of boards and committees for patient support organizations and dermatologic societies.

A note from Dr. Craiglow:  While most conditions in dermatology are not life-threatening, they can be dramatically life-altering.  I believe strongly in treating the patient, not just the disease. Every patient and family’s experience is unique, and there is no one-size-fits-all treatment. I pride myself on getting to know my patients and their families, spending time to educate about their condition and treatment options and advocating for their health. I am often the “last stop on the train” for patients with rare, severe and/or challenging-to-manage skin conditions and work tirelessly to help them achieve wellness.

EDUCATION & TRAINING

• BA, Yale University
• MD, Yale School of Medicine
• Dermatology Residency, Yale-New Haven Hospital
• Pediatric Dermatology Fellowship, Yale-New Haven Hospital

SELECTED RECENT PUBLICATIONS

You can find a full list of publications here.

King BA, Mesinkovska NA, Craiglow B, Kindred C et al. Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort. J Am Acad Dermatol. 2021 Aug 30. 2022 Feb;86(2):359-364.

Peterson D, Craiglow BG, Mesinkovska NA, Ko J, Senna MM, King B. It’s all alopecia areata – it’s time to abandon the terms alopecia totalis and alopecia universalis. J Am Acad Dermatol. 2021 Oct 19 Epub ahead of print.

Cho SK, Craiglow BG. Dupilumab for the treatment of alopecia areata in children with atopic dermatitis. JAAD Case Rep. 2021 Jul 27;16:82-85.

Kim SR, Craiglow BG. Repigmentation of vitiligo-associated eyelash leukotrichia with topical tofacitinib. JAAD Case Rep. 2021 Jul 27;16:90-91.

Olamiju B, Craiglow BG. Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls.  J Am Acad Dermatol. 2021 June 84(6): 1689-1691.

Olamiju B, Craiglow BG.  Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.  Pediatr Dermatol. 2020;37(4):754-755.

Hamilton CE, Craiglow BG. JAK inhibitors for the treatment of pediatric alopecia areata. J Investig Dermatol Symp Proc. 2020 Nov;20(1):S31-S36.

Wambier CG, Craiglow BG, King BA.  Combination tofacitinib and oral minoxidil treatment for severe alopecia areata.  J Am Acad Dermatol. 2019 Sep 6:S0190-9622(19)32688-X

Craiglow BG, King BA.  Tofacitinib for the treatment of alopecia areata in preadolescent children.  J Am Acad Dermatol. 2019;80:568-570.

Kim SR, Kibbi N, Craiglow BG.  Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient.  JAAD Case Rep. 2019;5:552-554.

Craiglow BG, Boyden LM, Hu R, Virtanen M, et al. CARD14-associated papulosquamous eruption (CAPE): A Spectrum Including Features of Psoriasis and Pityriasis Rubra Pilaris.  J Am Acad Dermatol. 2018;487-494.

Liu LY, King BA, Craiglow BG.  Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children, and their families.  J Am Acad Dermatol. 2018;79:556-558.

Craiglow BG.  Tofacitinib 2% solution for the treatment of alopecia areata affecting eyelashes.  JAAD Case Rep.  2018;78:403-404.

Glick J, Craiglow BG, Choate KA, Kato H et al.  Improved Management of Harlequin Ichthyosis with Advances in Neonatal Intensive Care. Pediatrics. 2017;139: e20161003.

Craiglow BG, Liu LY, King BA.  Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76:29-32.

Liu LY, Craiglow BG, Dai F, King BA.  Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.  J Am Acad Dermatol. 2017;76:22-28.

Liu LL, King BA, Craiglow BG. Health-related quality of life among patients with alopecia areata: a systematic review. J Am Acad Dermatol.  2016;75:806-812.e3.

Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol. 2016;152:490-1.

Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: A Pathogenesis-Directed Therapy.  JAMA Dermatol. 2015;151:1110-2.

Craiglow BG, King BA.  Killing two birds with one stone: topical tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.  J Invest Derm.  2014;134:2988-90.

New patients must call the office to schedule their first appointment
(203) 292-9490.